Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Analysis of Profitability Ratios
Quarterly Data

Beginner level


Profitability Ratios (Summary)

Regeneron Pharmaceuticals Inc., profitability ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Return on Sales
Gross profit margin 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43%
Operating profit margin 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51%
Net profit margin 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50%
Return on Investment
Return on equity (ROE) 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40%
Return on assets (ROA) 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Regeneron Pharmaceuticals Inc.’s gross profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Regeneron Pharmaceuticals Inc.’s operating profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Regeneron Pharmaceuticals Inc.’s net profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Regeneron Pharmaceuticals Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
ROA A profitability ratio calculated as net income divided by total assets. Regeneron Pharmaceuticals Inc.’s ROA improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Gross Profit Margin

Regeneron Pharmaceuticals Inc., gross profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Gross profit 1,676,500  1,610,900  1,945,600  1,821,800  1,781,200  1,532,600  1,810,625  1,553,127  1,516,361  1,396,587  1,476,707  1,396,441  1,367,195  1,234,823  1,152,146  1,175,894  1,143,596  1,089,097  987,246  1,028,339  909,777  785,657 
Revenues 1,952,000  1,828,200  2,169,500  2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612 
Profitability Ratio
Gross profit margin1 88.21% 89.72% 90.05% 91.14% 92.27% 92.79% 93.53% 93.36% 93.28% 92.95% 93.24% 93.37% 94.16% 94.53% 93.83% 92.90% 91.38% 90.52% 90.43%
Benchmarks
Gross Profit Margin, Competitors2
Abbott Laboratories 50.97% 52.13% 52.46% 52.39% 52.17% 51.57% 51.32% 50.57% 50.38% 49.39% 47.75% 48.59% 49.21% 51.32% 54.09% 54.17% 53.99% 53.93% 54.19%
AbbVie Inc. 73.56% 77.43% 77.64% 77.32% 77.41% 77.07% 76.44% 75.22% 74.93% 75.18% 75.05% 76.85% 76.78% 76.81% 77.25% 77.21% 78.12% 79.28% 80.31%
Amgen Inc. 77.15% 78.90% 80.38% 81.19% 81.23% 81.26% 81.80% 81.61% 81.78% 81.69% 81.33% 81.37% 81.26% 81.05% 80.99% 80.68% 80.64% 80.23% 79.82%
Biogen Inc. 87.97% 87.47% 86.40% 85.97% 85.59% 85.72% 86.50% 86.12% 86.43% 86.57% 86.72% 87.34% 86.80% 86.56% 87.08% 87.46% 88.21% 88.65% 88.48%
Bristol-Myers Squibb Co. 69.59% 68.08% 69.10% 69.65% 69.93% 70.77% 70.98% 70.37% 70.12% 69.62% 70.80% 71.92% 72.78% 74.19% 74.54% 75.56% 75.55% 75.67% 76.39%
Eli Lilly & Co. 78.67% 79.22% 78.85% 77.78% 76.67% 74.96% 73.81% 73.39% 72.92% 72.95% 73.46% 73.69% 73.89% 73.78% 73.35% 73.23% 73.72% 74.39% 74.76%
Gilead Sciences Inc. 78.25% 79.06% 78.86% 79.27% 78.98% 78.02% 77.61% 79.21% 80.31% 81.82% 82.97% 84.51% 84.71% 85.95% 85.77% 86.36% 86.91% 86.69% 87.54%
Illumina Inc. 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48% 69.91% 69.96% 69.74% 69.80%
Johnson & Johnson 65.66% 66.15% 66.42% 66.49% 66.67% 66.80% 66.79% 66.36% 65.69% 66.22% 66.84% 68.20% 69.35% 69.88% 69.84% 69.52% 69.58% 69.25% 69.27%
Merck & Co. Inc. 70.06% 70.11% 69.87% 70.13% 69.89% 68.94% 68.06% 67.35% 67.81% 68.22% 68.16% 68.09% 67.92% 66.61% 65.10% 63.89% 62.58% 62.07% 62.19%
Pfizer Inc. 79.94% 79.94% 80.25% 79.85% 79.91% 79.36% 79.03% 78.58% 78.24% 78.48% 78.61% 78.66% 78.15% 77.28% 76.66% 76.48% 77.71% 79.09% 80.25%
Vertex Pharmaceuticals Inc. 87.71% 87.24% 86.84% 86.60% 86.56% 86.74% 86.56% 86.88% 87.31% 87.59% 88.95% 89.04% 89.08% 89.76% 87.64% 87.16% 87.72% 87.39% 87.94%
Zoetis Inc. 69.73% 69.51% 68.18% 67.38% 66.92% 66.49% 67.19% 68.12% 68.04% 67.31% 66.55% 65.14% 64.91% 65.30% 65.92% 65.32% 64.90% 64.08% 63.53%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Gross profit margin = 100 × (Gross profitQ2 2020 + Gross profitQ1 2020 + Gross profitQ4 2019 + Gross profitQ3 2019) ÷ (RevenuesQ2 2020 + RevenuesQ1 2020 + RevenuesQ4 2019 + RevenuesQ3 2019)
= 100 × (1,676,500 + 1,610,900 + 1,945,600 + 1,821,800) ÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400) = 88.21%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Regeneron Pharmaceuticals Inc.’s gross profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Operating Profit Margin

Regeneron Pharmaceuticals Inc., operating profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Income from operations 656,400  700,100  675,700  738,500  315,600  480,000  718,058  626,923  622,188  567,231  538,811  559,926  550,312  430,542  347,003  362,802  291,628  329,308  231,082  392,422  344,859  283,553 
Revenues 1,952,000  1,828,200  2,169,500  2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612 
Profitability Ratio
Operating profit margin1 34.64% 30.45% 28.10% 29.55% 29.58% 35.41% 37.77% 37.00% 36.89% 36.54% 35.41% 34.22% 32.29% 28.76% 27.38% 25.67% 26.77% 29.26% 30.51%
Benchmarks
Operating Profit Margin, Competitors2
Abbott Laboratories 12.78% 14.18% 14.21% 13.74% 13.27% 12.31% 11.94% 10.45% 10.11% 8.92% 6.30% 7.89% 8.77% 11.03% 15.27% 14.74% 13.95% 13.64% 14.05%
AbbVie Inc. 30.17% 39.86% 39.03% 20.04% 21.85% 19.88% 19.49% 32.99% 32.84% 34.03% 33.99% 37.24% 36.74% 36.33% 36.60% 36.21% 35.00% 34.18% 32.97%
Amgen Inc. 39.76% 41.89% 43.57% 44.83% 44.05% 44.53% 45.55% 45.82% 46.46% 46.07% 45.76% 46.66% 46.93% 45.68% 44.74% 43.33% 42.46% 41.53% 40.44%
Biogen Inc. 50.93% 51.03% 48.98% 47.13% 46.90% 42.40% 43.77% 44.67% 45.58% 46.49% 43.54% 40.25% 38.72% 41.59% 44.99% 47.59% 47.86% 47.11% 45.44%
Bristol-Myers Squibb Co. 11.67% 16.30% 22.62% 28.64% 28.60% 23.44% 22.69% 18.64% 15.93% 17.50% 17.39% 19.71% 21.73% 24.06% 23.83% 19.21% 16.34% 11.09% 11.41%
Eli Lilly & Co. 24.48% 25.64% 22.29% 20.00% 19.48% 12.50% 15.15% 12.34% 9.11% 14.88% 9.38% 12.43% 14.23% 12.92% 16.30% 14.31% 14.56% 14.27% 13.47%
Gilead Sciences Inc. -4.40% 19.89% 19.38% 19.71% 38.44% 37.87% 37.83% 42.81% 46.25% 51.51% 55.04% 58.72% 58.71% 58.46% 58.87% 61.67% 63.83% 66.22% 69.03%
Illumina Inc. 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48% 24.80% 24.55% 24.77% 27.61%
Johnson & Johnson 24.64% 25.62% 24.15% 24.15% 22.63% 22.69% 24.27% 22.59% 23.05% 23.63% 24.07% 27.02% 28.55% 28.83% 28.72% 26.37% 25.66% 25.00% 25.05%
Merck & Co. Inc. 25.40% 25.49% 24.77% 25.56% 26.73% 24.38% 19.62% 17.84% 12.28% 13.57% 16.28% 9.92% 16.85% 14.45% 13.51% 19.60% 18.10% 18.19% 17.54%
Pfizer Inc. 23.75% 25.38% 25.46% 26.30% 27.50% 26.86% 26.10% 26.18% 26.00% 25.86% 25.92% 24.69% 23.57% 22.94% 22.73% 22.96% 24.02% 24.86% 24.20%
Vertex Pharmaceuticals Inc. 38.67% 34.05% 28.77% 21.38% 25.48% 23.98% 20.84% 22.38% 3.87% -0.77% 4.95% 1.62% 16.16% 14.62% 0.58% -5.02% -8.65% -23.94% -45.23%
Zoetis Inc. 33.36% 32.72% 31.42% 31.01% 29.80% 30.05% 31.12% 33.00% 33.86% 33.02% 32.15% 29.43% 28.34% 28.55% 28.48% 26.22% 24.91% 17.35% 15.74%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Operating profit margin = 100 × (Income from operationsQ2 2020 + Income from operationsQ1 2020 + Income from operationsQ4 2019 + Income from operationsQ3 2019) ÷ (RevenuesQ2 2020 + RevenuesQ1 2020 + RevenuesQ4 2019 + RevenuesQ3 2019)
= 100 × (656,400 + 700,100 + 675,700 + 738,500) ÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400) = 34.64%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Regeneron Pharmaceuticals Inc.’s operating profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Net Profit Margin

Regeneron Pharmaceuticals Inc., net profit margin calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income 897,300  624,600  792,000  669,600  193,100  461,100  820,353  594,655  551,412  477,980  173,519  388,317  387,744  248,931  253,115  264,804  196,218  181,385  154,994  210,398  194,643  76,021 
Revenues 1,952,000  1,828,200  2,169,500  2,048,400  1,933,700  1,711,800  1,927,797  1,663,496  1,608,022  1,511,485  1,582,447  1,500,673  1,470,116  1,318,991  1,226,827  1,220,122  1,212,629  1,200,849  1,098,077  1,137,422  998,617  869,612 
Profitability Ratio
Net profit margin1 37.30% 28.56% 26.91% 28.13% 28.59% 35.12% 36.42% 28.24% 25.65% 23.54% 20.41% 23.17% 22.05% 19.34% 18.42% 16.85% 15.98% 16.72% 15.50%
Benchmarks
Net Profit Margin, Competitors2
Abbott Laboratories 9.89% 11.15% 11.56% 10.50% 9.36% 8.53% 7.74% 2.91% 3.13% 1.67% 1.74% 8.37% 4.96% 6.74% 6.71% 6.61% 11.08% 12.00% 21.68%
AbbVie Inc. 19.20% 24.77% 23.69% 9.90% 12.62% 16.42% 17.36% 23.50% 20.84% 21.55% 18.82% 24.38% 24.77% 24.07% 23.22% 24.08% 23.11% 23.03% 22.50%
Amgen Inc. 31.53% 33.64% 35.32% 36.14% 35.57% 35.93% 37.25% 9.96% 10.72% 10.11% 9.08% 37.36% 37.24% 36.12% 35.27% 35.19% 34.48% 33.86% 33.13%
Biogen Inc. 40.91% 40.76% 40.96% 37.91% 37.62% 33.79% 32.93% 24.08% 23.06% 23.54% 20.69% 29.44% 28.10% 30.17% 32.34% 34.03% 33.97% 33.79% 32.95%
Bristol-Myers Squibb Co. -1.61% 3.08% 13.15% 23.39% 26.00% 22.09% 21.81% 6.50% 1.74% 4.37% 4.85% 20.56% 22.66% 24.22% 22.94% 18.22% 16.29% 9.31% 9.45%
Eli Lilly & Co. 24.48% 23.97% 37.27% 35.10% 33.76% 26.12% 13.16% 1.85% -0.60% 4.82% -0.89% 9.90% 11.12% 10.13% 12.90% 11.73% 11.97% 11.49% 12.07%
Gilead Sciences Inc. -1.18% 22.17% 24.35% 12.24% 27.14% 26.93% 25.16% 7.27% 9.69% 14.26% 18.03% 42.90% 43.55% 44.11% 45.07% 48.40% 51.16% 53.48% 56.32%
Illumina Inc. 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29% 18.70% 18.70% 18.40% 20.79%
Johnson & Johnson 18.86% 20.75% 18.42% 17.32% 20.08% 17.99% 18.75% 1.89% 1.70% 1.58% 1.70% 21.28% 22.52% 22.87% 23.01% 22.27% 21.20% 22.15% 21.99%
Merck & Co. Inc. 22.20% 21.10% 21.01% 20.26% 21.10% 19.50% 14.71% 8.02% 3.25% 3.88% 5.97% 7.15% 12.71% 10.88% 9.85% 13.76% 13.01% 11.72% 11.25%
Pfizer Inc. 28.80% 31.17% 31.45% 30.57% 23.58% 21.31% 20.79% 44.63% 42.35% 41.29% 40.55% 18.69% 15.90% 13.88% 13.66% 11.77% 13.47% 14.95% 14.25%
Vertex Pharmaceuticals Inc. 38.51% 31.35% 28.27% 59.23% 64.13% 66.01% 68.80% 22.87% 15.84% 9.36% 10.59% 8.53% 12.19% 8.78% -6.58% -13.17% -17.66% -30.91% -53.89%
Zoetis Inc. 25.50% 25.41% 23.96% 23.76% 22.74% 23.47% 24.52% 20.35% 19.95% 17.97% 16.28% 18.29% 17.50% 17.25% 16.80% 14.10% 13.15% 7.83% 7.11%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
Net profit margin = 100 × (Net incomeQ2 2020 + Net incomeQ1 2020 + Net incomeQ4 2019 + Net incomeQ3 2019) ÷ (RevenuesQ2 2020 + RevenuesQ1 2020 + RevenuesQ4 2019 + RevenuesQ3 2019)
= 100 × (897,300 + 624,600 + 792,000 + 669,600) ÷ (1,952,000 + 1,828,200 + 2,169,500 + 2,048,400) = 37.30%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Regeneron Pharmaceuticals Inc.’s net profit margin ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Return on Equity (ROE)

Regeneron Pharmaceuticals Inc., ROE calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income 897,300  624,600  792,000  669,600  193,100  461,100  820,353  594,655  551,412  477,980  173,519  388,317  387,744  248,931  253,115  264,804  196,218  181,385  154,994  210,398  194,643  76,021 
Stockholders’ equity 9,057,400  12,133,000  11,089,700  10,504,400  9,755,900  9,444,700  8,757,300  7,868,300  7,186,426  6,567,644  6,144,078  6,051,593  5,520,738  4,866,021  4,449,245  4,491,247  4,076,506  3,765,082  3,654,837  3,296,867  3,338,458  2,971,430 
Profitability Ratio
ROE1 32.94% 18.79% 19.08% 20.41% 21.21% 25.70% 27.91% 22.85% 22.14% 21.74% 19.51% 21.12% 20.91% 19.79% 20.13% 17.75% 18.23% 19.69% 17.40%
Benchmarks
ROE, Competitors2
Abbott Laboratories 10.17% 11.84% 11.86% 10.35% 9.14% 8.48% 7.76% 2.89% 3.03% 1.52% 1.54% 6.57% 3.71% 4.79% 6.82% 6.59% 11.02% 11.81% 20.85%
AbbVie Inc. 47.30% 179.59% 104.16% 99.42% 110.08% 126.25% 128.41% 93.97% 101.42% 117.94% 130.39%
Amgen Inc. 68.48% 80.92% 81.07% 73.83% 73.73% 74.55% 67.15% 15.35% 15.86% 14.21% 7.84% 25.37% 25.77% 25.76% 25.85% 24.65% 24.67% 25.16% 24.71%
Biogen Inc. 52.41% 46.85% 44.13% 38.55% 40.87% 33.74% 33.98% 23.15% 24.21% 21.09% 20.13% 27.10% 28.42% 30.31% 30.50% 32.06% 33.48% 35.78% 37.84%
Bristol-Myers Squibb Co. -1.15% 1.91% 6.66% 32.04% 38.65% 33.80% 35.07% 10.50% 3.05% 7.18% 8.58% 28.61% 31.20% 33.55% 27.55% 21.56% 19.24% 10.94% 10.97%
Eli Lilly & Co. 137.26% 179.72% 319.09% 234.97% 282.08% 252.24% 32.88% 3.44% -1.24% 7.74% -1.76% 14.94% 17.35% 15.58% 19.54% 15.68% 16.85% 15.45% 16.53%
Gilead Sciences Inc. -1.43% 22.49% 23.91% 13.07% 26.33% 26.84% 25.51% 6.94% 10.19% 16.82% 22.64% 46.69% 53.86% 61.82% 71.48% 89.38% 105.21% 129.43% 97.70%
Illumina Inc. 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06% 19.79% 21.05% 20.82% 24.97%
Johnson & Johnson 24.11% 28.01% 25.42% 24.31% 26.87% 24.90% 25.60% 2.39% 2.18% 1.97% 2.16% 21.39% 22.71% 23.46% 23.49% 21.91% 20.73% 21.40% 21.66%
Merck & Co. Inc. 37.91% 38.72% 37.99% 34.70% 33.88% 30.50% 23.30% 10.32% 4.12% 4.69% 6.97% 7.44% 12.89% 10.91% 9.78% 12.55% 11.84% 10.53% 9.94%
Pfizer Inc. 22.02% 24.28% 25.77% 24.91% 21.24% 19.52% 17.59% 33.40% 32.31% 29.72% 29.88% 16.14% 14.26% 12.49% 12.12% 9.90% 11.22% 12.09% 10.75%
Vertex Pharmaceuticals Inc. 27.67% 23.38% 19.34% 40.81% 43.70% 45.63% 47.28% 22.27% 15.46% 9.41% 12.99% 10.93% 15.55% 11.82% -9.69% -21.41% -28.03% -41.73% -59.19%
Zoetis Inc. 54.23% 58.52% 55.39% 54.56% 57.03% 59.91% 65.35% 54.96% 56.60% 49.90% 48.81% 47.11% 51.20% 53.14% 55.21% 43.47% 47.09% 32.45% 31.74%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
ROE = 100 × (Net incomeQ2 2020 + Net incomeQ1 2020 + Net incomeQ4 2019 + Net incomeQ3 2019) ÷ Stockholders’ equity
= 100 × (897,300 + 624,600 + 792,000 + 669,600) ÷ 9,057,400 = 32.94%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Regeneron Pharmaceuticals Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 but then improved from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Return on Assets (ROA)

Regeneron Pharmaceuticals Inc., ROA calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in thousands)
Net income 897,300  624,600  792,000  669,600  193,100  461,100  820,353  594,655  551,412  477,980  173,519  388,317  387,744  248,931  253,115  264,804  196,218  181,385  154,994  210,398  194,643  76,021 
Total assets 14,428,700  15,757,500  14,805,200  13,939,300  13,173,600  12,854,800  11,734,500  10,805,613  9,951,980  9,372,696  8,764,286  8,701,215  8,106,373  7,817,365  6,973,466  6,828,019  6,204,906  5,904,460  5,609,132  5,182,915  4,526,970  4,198,573 
Profitability Ratio
ROA1 20.68% 14.46% 14.29% 15.38% 15.71% 18.88% 20.83% 16.64% 15.99% 15.23% 13.67% 14.69% 14.24% 12.32% 12.84% 11.68% 11.97% 12.56% 11.34%
Benchmarks
ROA, Competitors2
Abbott Laboratories 4.52% 5.36% 5.43% 4.80% 4.23% 3.88% 3.53% 1.24% 1.35% 0.67% 0.63% 2.91% 1.65% 2.12% 2.66% 3.47% 5.72% 6.17% 10.72%
AbbVie Inc. 4.65% 9.25% 8.84% 5.48% 7.21% 9.44% 9.58% 11.43% 10.46% 9.20% 7.50% 9.66% 9.87% 9.61% 9.01% 9.12% 8.51% 10.19% 9.70%
Amgen Inc. 11.23% 12.45% 13.13% 13.55% 13.40% 12.62% 12.64% 3.27% 3.49% 3.12% 2.48% 10.18% 10.27% 10.14% 9.95% 9.71% 9.85% 9.61% 9.69%
Biogen Inc. 23.23% 22.51% 21.62% 19.63% 20.14% 17.65% 17.52% 12.50% 12.39% 11.36% 10.73% 15.11% 15.13% 16.42% 16.19% 17.58% 17.75% 17.87% 18.19%
Bristol-Myers Squibb Co. -0.44% 0.74% 2.65% 9.85% 11.24% 14.77% 14.06% 4.24% 1.15% 2.78% 3.00% 12.45% 13.73% 14.68% 13.22% 9.98% 8.74% 4.94% 4.93%
Eli Lilly & Co. 13.39% 13.46% 21.17% 20.97% 20.28% 16.46% 7.36% 1.01% -0.34% 2.53% -0.45% 5.17% 5.98% 5.81% 7.05% 6.50% 6.76% 6.68% 6.77%
Gilead Sciences Inc. -0.46% 8.31% 8.74% 4.55% 9.42% 9.38% 8.57% 2.47% 3.38% 5.30% 6.58% 17.94% 20.27% 21.90% 23.70% 26.63% 32.71% 36.30% 34.93%
Illumina Inc. 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81% 10.49% 10.86% 10.93% 12.52%
Johnson & Johnson 9.59% 11.07% 9.59% 9.10% 10.53% 9.78% 10.00% 0.99% 0.88% 0.79% 0.83% 10.17% 10.69% 11.39% 11.71% 11.36% 10.75% 11.41% 11.55%
Merck & Co. Inc. 11.56% 11.95% 11.66% 11.18% 11.15% 10.20% 7.53% 3.93% 1.58% 1.84% 2.72% 3.11% 5.48% 4.50% 4.11% 5.58% 5.32% 4.67% 4.36%
Pfizer Inc. 7.96% 9.49% 9.72% 9.51% 8.10% 7.38% 7.00% 14.19% 13.67% 13.21% 12.40% 5.70% 4.94% 4.32% 4.20% 3.51% 4.13% 4.68% 4.16%
Vertex Pharmaceuticals Inc. 20.37% 16.99% 14.15% 28.53% 31.50% 32.94% 33.57% 14.00% 9.58% 5.72% 7.43% 6.12% 7.91% 6.02% -3.87% -8.38% -10.79% -16.05% -22.26%
Zoetis Inc. 12.37% 13.97% 12.99% 12.96% 12.52% 12.75% 13.25% 11.13% 12.96% 11.25% 10.06% 10.09% 11.25% 11.18% 10.73% 8.93% 8.50% 5.07% 4.28%

Based on: 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-05), 10-K (filing date: 2020-02-07), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-07), 10-K (filing date: 2019-02-07), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-03), 10-K (filing date: 2018-02-08), 10-Q (filing date: 2017-11-08), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-04), 10-K (filing date: 2017-02-09), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-05), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-04), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-07).

1 Q2 2020 Calculation
ROA = 100 × (Net incomeQ2 2020 + Net incomeQ1 2020 + Net incomeQ4 2019 + Net incomeQ3 2019) ÷ Total assets
= 100 × (897,300 + 624,600 + 792,000 + 669,600) ÷ 14,428,700 = 20.68%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Regeneron Pharmaceuticals Inc.’s ROA improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.